Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study

Similar documents
EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy

Recent Update in Surgery for the Management of Breast Cancer

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center

Ultrasound or FNA for Predicting Node Positive in Breast Cancer

CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?

Financial Disclosure. Learning Objectives. None. To understand the clinical applicability of the NCDB Breast Cancer PUF

Surgical Issues in Neoadjuvant Chemotherapy

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery

Axillary ultrasound is frequently used to assess axillary nodes at

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

ARROCase - April 2017

Surgical Considera0ons with Neoadjuvant Treatment in Breast Cancer

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Saima Saeed MD

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?

Sentinel Lymph Node Biopsy for Breast Cancer

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.

Donna Plecha, MD 1, Shiyu Bai, BS 2, Helen Patterson 3, Cheryl Thompson, PhD 4, and Robert Shenk, MD 5

Results of the ACOSOG Z0011 Trial

Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection

Evaluation of the Axilla Post Z-0011 Trial New Paradigm

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016

NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Newly Diagnosed Breast Cancer: Preoperative Imaging and Localization

Neoadjuvant (Primary) Systemic Therapy

Problems in staging breast carcinoma

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

When do you need PET/CT or MRI in early breast cancer?

Loco-Regional Management After Neoadjuvant Chemotherapy

How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer

Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy

Practice of Axilla Surgery

Can We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D.

Updates on management of the axilla in breast cancer the surgical point of view

Savitri Krishnamurthy, MD 1

Update on the Surgical Management of Breast Cancer: What Happens After Imaging?

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

Loco-Regional Management After Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy (NACT) in young women with breast cancer. Hanne Melgaard Nielsen, MD Ph.D Department of Oncology, Aarhus University Hospital

SBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

M D..,., M. M P.. P H., H, F. F A.. A C..S..

Breast Imaging. Jamie L. Wagner, DO, FACOS. Digital vs Analog Mammography (2-D) Surgical Oncologist. Patient with Cancer. Radiology/ Interventional

Evaluation of the effect of neoadjuvant chemotherapy on tumor and axillary lymph nodes in locally advanced breast cancer: a study of 50 patients

Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients

BREAST CANCER SURGERY. Dr. John H. Donohue

Maria João Cardoso, MD, PhD

What the surgeon wants from the radiologist before breast cancer surgery. Erica Patocskai Isabelle Trop

Locally advanced BC: radiation therapy

Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy

PET/CT in breast cancer staging

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Sentinel lymph node biopsy under local anesthesia in patients with breast cancer

Ductal Carcinoma in Situ (DCIS)

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Study on Efficacy of Preoperative Ultrasonography for Axillary Lymph Node Involvement In Breast Carcinoma

Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Breast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland

Evolving Concepts in Breast Surgery in Multidisciplinary Care

BREAST SURGERY PROGRESS TEST Name:

Treating today s patients with tomorrow s solutions

COMPARATIVE ANALYSIS OF COLON AND RECTAL CANCERS IN SENTINEL LYMPH NODE MAPPING

Melanoma Quality Reporting

Neoadjuvant Treatment of. of Radiotherapy

Diagnosis and staging of breast cancer and multidisciplinary team working

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration

Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection

Image guided core biopsies:

Radionuclide detection of sentinel lymph node

How can surgeons help the Radiation Oncologists?

Pre- operative staging of the axilla

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Advances in Breast Cancer

Introduction. Hy-De Lee, MD, PhD 1 Sung Gwe Ahn, MD 1 Seung Ah Lee, MD 2 Hak Min Lee, MD 1 Joon Jeong, MD, PhD 1

Case Conference: Post-Mastectomy Radiotherapy

ROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER. B.Zandi Professor of Radiology

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial

EARLY BREAST CANCER, HER2-POSITIVE

Surgical Management of the Axilla

Conservative Surgery and Radiation Stage I and II Breast Cancer

Clinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair

EDITORIAL. Ann Surg Oncol (2011) 18: DOI /s

Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)

Axillary Reverse Mapping to Reduce the Incidence of Lymphedema

Page 1. AD vs. no AD. Survival. Randomized Trials. All trials reported higher survival in the AD group. Years. Node-NegativeNegative

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Transcription:

[ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong Lai Park 1, Chan Heun Park 1, In Young Youn 2, Seon Hyeong Choi 2, Yoon Jung Choi 2, Shin Ho Kook 2 Department of Surgery 1 and Radiology 2 Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine

Introduction Introduction Axilla restaging after neoadjuvant chemotherapy The extent of persistent axillary nodal disease after neoadjuvant chemotherapy (NAC) - established prognostic marker for locoregional recurrence and survival However, no clear consensus for reliable method (SLNB vs ALND) of restaging the axilla after NAC to confirm conversion to negative lymph node status Kuerer HM et al. Ann Surg Oncol. 2012 Von Minckwitz G. et al. J Clin Oncol. 2012

Introduction

Introduction Targeted axillary dissection after neoadjuvant chemotherapy To decrease false negative rate (FNR), targeted axillary dissection has been proposed NCCN Guidelines Version 4.2017 Marking of sampled axillary nodes with a tattoo or clip should be considered to permit verification that the biopsy-positive lymph node has been removed at the time of definitive surgery

Introduction 1. Mayo Clinic Clip placement in the positive node at initial diagnosis 2. Netherlands Radioactive iodine ( 125 I) seeds placement to axillary lymph node 3. MD Anderson Cancer Center Clip placement in the positive node at initial diagnosis

Introduction Accuracy of targeted axillary dissection after neoadjuvant chemotherapy ACOSOG Z1071 MARI TAD No of patients 141 100 208 Identification rate of clip in SLN 82.9% (141/170) 97.0% (97/100) 60.2% (115/191) FNR of clipped node 6.8% 7.0% 4.2% Boughey JC et al. Ann Surg. 2016 Donker M. et al. Ann Surg. 2015 Kuehn T et al. Lancet Oncol. 2013

Introduction Purpose To determine the feasibility of image-guided marker- clip placement in axillary lymph nodes (ALNs) for breast cancer on upon initial presentation To assess the reliability of this method with SLNB for axillary restaging after NAC

Materials and Methods Patients and Methods Prospective study from June 2015 to August 2016 - Women aged from 20-75 years who were diagnosed as breast cancer - Suspicious axillary LNs (thickened cortex or absent hilum) on US or PET-CT - US-guided FNA or core needle biopsy on LNs before initiation of NAC - Underwent NAC followed by surgery Exclusion criteria - Disease progression during NAC - Pregnant or plan for pregnancy - Patients refusal

Materials and Methods US-guided clip insertion Surgical clips (LigaClip) was inserted into the suspicious lymph node before NAC One day after the procedure and one day before surgery - unilateral digital mammography (MLO) to confirm the location of clip

Materials and Methods Wire localization of marker-clipped nodes 1 hour before surgery, a 21-G 7.5-cm hooked wire was inserted to retrieve the clips

Materials and Methods Wire localization of marker-clipped nodes Cone-beam CT (CBCT) was performed for the selected region of interest After hook- wire localization - repeatedly acquired CT images to confirm the location of the marker clip

Materials and Methods SLN and marker-clipped lymph node surgery After excision of the marker- clipped LNs - intraoperative palpation, inspection of the specimen by a surgeon, specimen radiography confirmed that the excised LNs contained the clip Conventional SLNB proceeded using dual tracers

Materials and Methods Pathologic assessment The nodal specimens evaluated intraoperatively - to identify marker-clipped LNs and SLNs Axillary LN dissection (ALND) proceeded - if more than two LNs (including marker-clip LNs and SLNs) were found to be metastatic during intraoperative frozen biopsy

Results Patient characteristics N = 20 Age, mean, y 44.6±7.3 (29-58) Clinical tumor size, 3.9±1.6 (1.7-7.0) mean, cm Suspicious LNs on US 1 2 3 Tumor histology IDC ILC DCIS Histologic grade 1 2 3 unspecified 2 8 10 18 1 1 6 8 4 2 Tumor subtype ER/PR-positive, HER2-negative ER-positive, HER2-positive HER2-enriched Triple-negative NAC regimen AC-T AC-TH TCHP Type of breast surgery Partial mastectomy Total mastectomy N = 20 6 8 3 3 9 8 3 8 12

Results Clip insertion and wire localization Total of 24 clips inserted in 20 patients -1 marker clip insertion :16 patients, 2 marker clips insertion : 4 patients Wire localization of marker clipped LNs was successfully performed in all 24 clips 23 clips were successfully retrieved intraoperatively (identification rate of marker clipped LNs, 23/24 =95.8%) However, 1 clip could not be found and retrieved intraoperatively - possibly due to loosening of the anchored hook The location of the clip that we failed to retrieve was confirmed on the 6-month follow-up chest CT at the placement site, without migration

Results Surgical Procedure and Pathologic Outcomes Size of marker-clipped LN, mean, cm Clips identified in SLN 17 Clips identified in ALN 6 SLNB performed 12 SLNB and ALND performed 8 N = 20 1.4±0.7 (0.3-3.0) No. of marker-clipped LNs 1.1±0.3 (1-2) removed, mean No. of SLNs removed, mean 2.2±1.8 (1-7) No. of ALNs removed, mean 6.7±5.2 (1-13) Pathological tumor size, mean, cm Pathological tumor response Complete (no residual tumor) Residual DCIS only Residual infiltrating ca 1 cm Residual infiltrating ca > 1 cm Pathological response of LN No residual tumor Metastatic residue N = 20 1.7±2.0 (0-9.5) 3 2 1 14 13 7 pcr of both primary tumor, LN 3

Results Clinicopathologic staging and pathologic status of ALNs before and after NAC Case Prechemo Clinical stage Postchemo Clinical stage Pathologic stage Prechemo Marker-clipped LN Postchemo Marker-clipped LN SLN ALN 1 T2N1 T1N1 ypt1n0 Negative Negative Negative Negative 2 T3N1 T2N0 ypt2n0 Negative Negative Negative 5 T1N1 T0N0 ypt0n0 Negative Negative Negative 6 T3N1 T3N0 ypt3n0 Negative Negative Negative 7 T2N1 T1N0 ypt0n0 Negative Negative Negative 10 T2N1 T2N1 ypt2n0 Negative Negative Negative 13 T2N1 T1N1 ypt1n0 Negative Negative Negative 17 T4N1 T2N0 ypt0n0 Negative Negative Negative Negative 19 T3N1 T2N1 ypt1n0 Negative Negative Negative

Results Clinicopathologic staging and pathologic status of ALNs before and after NAC Case Prechemo Clinical stage Postchemo Clinical stage Pathologic stage Prechemo Marker-clipped LN Postchemo Marker-clipped LN SLN ALN 3 T3N1 T2N1 ypt1n0 Positive Negative Negative Negative 4 T2N1 T1N0 ypt1n0 Positive Negative Negative 8 T2N1 T1N0 ypt1n1 Positive Positive Positive Negative 9 T2N2 T1N1 ypt1n1 Positive Positive Negative Positive 11 T2N2 T1N0 yptisn2 Positive Positive Positive Positive 12 T3N1 T2N1 ypt1n0 Positive Negative Negative 14 T2N1 T1N1 ypt2n1 Positive Positive Negative Negative 15 T2N1 T1N1 ypt1n1 Positive Positive Negative 16 T2N2 T1N1 ypt2n2 Positive Positive Negative Positive 18 T2N1 T2N1 ypt1n0 Positive Negative Negative 20 T2N1 T0N0 yptisn1 Positive Positive Negative

Results All patients were underwent follow-up exams for axillary recurrence until March, 2018 (mean : 24.3 months) Disease-free status of the axilla was confirmed in all 20 patients No complications (bleeding, hematoma formation, nerve injury) were reported during clip insertion or wire localization No intraoperative or postoperative complications were reported

Conclusion Conclusion Image-guided marker-clip placement on positive ALNs before NAC and removal with SLNB is technically feasible and safe This procedure can improve the accuracy of the residual disease evaluation of axilla, especially in patients who have negative SLNB results It can also identify candidates for limited axillary surgery after neoadjuvant chemotherapy

Conclusion Kim EY et al. World J Surg. 2017

Thank you for your attention